Matthew T Basel

US Patent:

20120157824, Jun 21, 2012

Filed:

Aug 31, 2010

Appl. No.:

13/393472

Inventors:

Stefan H. Bossmann - Manhattan KS, US
Deryl Troyer - Manhattan KS, US
Matthew T. Basel - Manhattan KS, US
Thilani Nishanthika Samarakoon - Manhattan KS, US
Hongwang Wang - Manhattan KS, US
Viktor Chikan - Manhattan KS, US
Franklin Orban Kroh - Wamego KS, US
Olga Barbara Koper - Dublin OH, US
Brandon Ray Walker - Wamego KS, US
Xiaoxuan Leaym - Manhattan KS, US

Assignee:

NANOSCALE CORPORATION - Manhattan KS
KANSAS STATE UNIVERSITY RESEARCH FOUNDATION - Manhattan KS

International Classification:

A61K 49/18
A61B 5/055

US Classification:

600420, 424 93, 424 932

Abstract:

The present invention provides multifunctional nanoplatforms for assessing the activity of a protease in vivo or in vitro, along with methods of imaging and detecting the presence of cancerous or precancerous tissues, and the therapeutic treatment thereof, including monitoring of treatment. The diagnostic nanoplatforms comprise nanoparticles and are linked to each other or other particles via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected using various sensors, and the diagnostic results can be correlated with cancer prognosis. Individual unlinked nanoplatforms are also adaptable for therapeutic hyperthermia treatment of the cancerous tissue.

US Patent:

20130183702, Jul 18, 2013

Filed:

Mar 13, 2013

Appl. No.:

13/800456

Inventors:

Kansas State University Research Foundation - Manhattan KS, US
Deryl L. Troyer - Manhattan KS, US
Matthew T. Basel - Manhattan KS, US
Tej B. Shrestha - Manhattan KS, US
Hongwang Wang - Manhattan KS, US

Assignee:

Kansas State University Research Foundation - Manhattan KS

International Classification:

C12Q 1/37
A61K 9/127
C12N 11/06

US Classification:

435 23, 435183, 435181

Abstract:

Supramolecular assemblies for delivering active agents to cancerous or precancerous tissues in a subject are provided. These supramolecular assemblies are also useful in assays for detecting and imaging of cancerous and precancerous cells. The assemblies are protease-sensitive and comprise a peptide linkage containing a protease consensus sequence. The assemblies can be selectively targeted to cancerous tissue where the protease enzymes degrade the peptide linkage thereby releasing the active agents which were physically or mechanically contained in or retained by the supramolecular assembly.

US Patent:

20130243741, Sep 19, 2013

Filed:

Sep 19, 2011

Appl. No.:

13/821516

Inventors:

Stefan H. Bossmann - Manhattan KS, US
Deryl L. Troyer - Manhattan KS, US
Matthew T. Basel - Manhattan KS, US
Tej B. Shrestha - Manhattan KS, US
Hongwang Wang - Manhattan KS, US

Assignee:

KANSAS STATE UNIVERSITY RESEARCH FOUNDATION - Manhattan KS

International Classification:

A61K 41/00

US Classification:

424 9321

Abstract:

A method for photodynamic therapy treatment of cancerous cells and tissue is provided. The method comprises administering tumor-trophic cells expressing a luminescent protein to a subject. A photosensitizing agent is then separately administered to the subject, followed by an optional iron chelator. On the day of treatment, a luminogenic substrate corresponding to the luminescent protein is administered to the subject. The substrate reacts with the luminescent protein in the vicinity of the cancerous tissue to produce light which activates the photosensitizing agent resulting in the selective destruction of the cancerous tissue.

US Patent:

20110014125, Jan 20, 2011

Filed:

Mar 3, 2009

Appl. No.:

12/920771

Inventors:

Stefan H. Bossmann - Manhattan KS, US
Deryl L. Troyer - Manhattan KS, US
Matthew T. Basel - Manhattan KS, US

Assignee:

KANSAS STATE UNIVERSITY RESEARCH FOUNDATION - Manhattan KS

International Classification:

A61K 49/00
C12N 11/00
C12N 11/14
C12N 11/02
C12Q 1/37

US Classification:

424 91, 435174, 435176, 435177, 435 24, 977773, 977774

Abstract:

The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.

US Patent:

20150224211, Aug 13, 2015

Filed:

Apr 23, 2015

Appl. No.:

14/694511

Inventors:

Deryl L. Troyer - , US
Stefan H. Bossmann - , US
Hongwang Wang - Manhattan KS, US
Matthew T. Basel - Manhattan KS, US
Tej B. Shrestha - Manhattan KS, US
Sebastian Wendel - Manhattan KS, US

International Classification:

A61K 49/00
A61K 9/127
A61K 47/46
A61K 41/00
A61K 31/65

Abstract:

Theranostic methods are described herein, which are useful in diagnosing and/or treating infection, inflammation, and/or cancer. The methods utilize naturally-occurring leukocytes for in situ photodynamic therapy and imaging, and for the delivery of targeted therapies to the infection, inflammation, and/or cancer.

US Patent:

20150132230, May 14, 2015

Filed:

Jan 26, 2015

Appl. No.:

14/605083

Inventors:

- Manhattan KS, US
Deryl L. Troyer - Manhattan KS, US
Matthew T. Basel - Manhattan KS, US

International Classification:

A61K 49/00

US Classification:

424 961, 424 96, 424 91, 977774, 977920

Abstract:

The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.

US Patent:

20150132785, May 14, 2015

Filed:

Jan 26, 2015

Appl. No.:

14/605039

Inventors:

- Manhattan KS, US
Deryl L. Troyer - Manhattan KS, US
Matthew T. Basel - Manhattan KS, US

International Classification:

C12Q 1/37
G01N 33/58

US Classification:

435 23

Abstract:

The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.